ReviewCancer science2021
Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.
Review in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Establishment and characterization of NCC-GCTB16-C1: novel patient-derived cell line of giant cell tumor of bone.Human cell · 2026Article
- Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Review
- Gastric cancer organoids: a promising model for personalized treatment of gastric cancer.Frontiers in cell and developmental biology · 2025Review
- Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1.Human cell · 2024Article
- Article
- Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma.Human cell · 2024Article
- Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.Human cell · 2024Article
- Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.Cell death & disease · 2024Article
- Challenges and opportunities in rare cancer research in China.Science China. Life sciences · 2024Review
- Implementation status of pharmacological studies in the development of orphan drugs.Orphanet journal of rare diseases · 2024Article
- Ethical considerations for nurses working in rare cancer care: Focus on sarcoma.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2024Article
- Landscape of Genetic Mutations in Appendiceal Cancers.Cancers · 2023Review
- Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs.International journal of molecular sciences · 2023Article
- Immunotherapies in rare cancers.Molecular cancer · 2023Review
- Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.Biomolecules · 2023Review
- Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.Human cell · 2022Article
- The CAM Model forCells · 2021Article
- Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.Human cell · 2021Article
- Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.Cancer science · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Rare cancers are a group of approximately 200 malignancies with extremely low incidences and with a wide variety of genotypes and phenotypes. Collectively, they are more common than any single malignancy. However, given the small numbers of individuals diagnosed with rare cancers, it is difficult to design clinical trials with sufficient patient numbers. Therefore, few effective anticancer drugs have been developed, and evidence-based medicine is not always feasible for rare cancers. Consequently, their clinical outcomes are generally poorer. Cancer research requires adequate models that faithfully recapitulate molecular features and reproduce treatment responses of the original tumors. Such models allow us to focus on more efficacious drugs in the clinical studies. For rare cancers, patient-derived cancer models are particularly important because the enrollment of sufficient patients is rarely attainable within a reasonable period of time. However, extremely few models are available for rare cancers. For example, cell lines and xenografts are available for only a limited number of histological subtypes of sarcomas; therefore, most sarcoma research is performed without such models, and a lack of adequate cancer models causes a lag in therapeutic development. The establishment of novel rare cancer models will dramatically facilitate rare cancer research and treatment development in the near future. This review focuses on the status of patient-derived rare cancer models and discusses their pivotal problems and possibilities, using sarcomas as a representative rare cancer type. Multi-institutional collaboration will help address the scarcity of patient-derived rare cancer models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.